Open Access

This article has an erratum: [https://doi.org/10.1051/mbcb/2023035]


Issue
J Oral Med Oral Surg
Volume 29, Number 3, 2023
Article Number 28
Number of page(s) 9
DOI https://doi.org/10.1051/mbcb/2023025
Published online 31 August 2023
  1. Food US, Administration D. Commissioner Scott Gottlieb. The FDA's Biosimilars Action Plan 2018. Brookings Institution, Washington, DC. https://www.fda.gov/news-events/press-announcements/remarks-fda-commissioner-scott-gottlieb-md-prepared-delivery-brookings-institution-release-fdas [Accessibility verified November 14, 2021] [Google Scholar]
  2. O'Neill ID, Scully C. Biologics in oral medicine: principles of use and practical considerations. Oral Dis 2012;18:525–536. [CrossRef] [PubMed] [Google Scholar]
  3. Ho DY, Subramanian AK. Infections related to biologics. Infect Dis Clin N Am 2020;34:xiii–xvi. [Google Scholar]
  4. Zaghiyan K, McGovern D, Fleshner P. Should biologic agents be stopped before surgery for inflammatory bowel disease? Expert Rev Gastroenterol Hepatol 2015;9:269–272. [CrossRef] [PubMed] [Google Scholar]
  5. Smith CH, Yiu ZZN, Bale T, et al. British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020-a rapid update. Br J Dermatol 2020;183:628–637. [CrossRef] [PubMed] [Google Scholar]
  6. Goodman SM, Springer B, Guyatt G, et al. American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty. Arthritis Rheumatol 2017;69:1538–1551. [CrossRef] [PubMed] [Google Scholar]
  7. Lortholary O, Fernandez-Ruiz M, Baddley JW, et al. Infectious complications of rheumatoid arthritis and psoriatic arthritis during targeted and biological therapies: a viewpoint in 2020. Ann Rheum Dis 2020;79:1532–1543. [CrossRef] [PubMed] [Google Scholar]
  8. Abou Zahr Z, Spiegelman A, Cantu M, et al. Perioperative use of anti-rheumatic agents does not increase early postoperative infection risks: a Veteran Affairs' administrative database study. Rheumatol Int 2015;35:265–272. [CrossRef] [PubMed] [Google Scholar]
  9. Bafford AC, Powers S, Ha C, et al. Immunosuppressive therapy does not increase operative morbidity in patients with Crohn's disease. J Clin Gastroenterol 2013;47:491–495. [CrossRef] [PubMed] [Google Scholar]
  10. Scott DL. Biologics-based therapy for the treatment of rheumatoid arthritis. Clin Pharmacol Ther 2011;91:30–43. [Google Scholar]
  11. George MD, Baker JF, Hsu JY, et al. Perioperative timing of infliximab and the risk of serious infection after elective hip and knee arthroplasty. Arthritis Care Res (Hoboken) 2017;69:1845-1854. [CrossRef] [PubMed] [Google Scholar]
  12. Lau C, Dubinsky M, Melmed G, et al. The impact of preoperative serum anti-TNFα therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. Ann Surg 2015;261:487-496. [CrossRef] [PubMed] [Google Scholar]
  13. Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis. Rheumatology 2019;58:e3–e42. [CrossRef] [PubMed] [Google Scholar]
  14. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. Foot Ankle Int 2004;25:331–335. [CrossRef] [PubMed] [Google Scholar]
  15. Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum 2008;59:1713–1720. [CrossRef] [PubMed] [Google Scholar]
  16. den Broeder AA, Creemers MC, Fransen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. J Rheumatol 2007;34:689–695. [PubMed] [Google Scholar]
  17. Cohen BL, Fleshnet P, Kane SV, et al. Anti-tumor necrosis factor therapy is not associated with post-operative infection: results from prospective cohort of ulcerative colitis and Crohn's disease patients undergoing surgery to identify risk factors for postoperative infection. Gastroenterology 2019;156:S80. [Google Scholar]
  18. Gainsbury ML, Chu DI, Howard LA, et al. Preoperative infliximab is not associated with an increased risk of short-term postoperative complications after restorative proctocolectomy and ileal pouch-anal anastomosis. J Gastrointest Surg 2011;15:397–403. [CrossRef] [PubMed] [Google Scholar]
  19. George MD, Baker JF, Winthrop K, et al. Timing of abatacept before elective arthroplasty and risk of postoperative outcomes. Arthritis Care Res 2019;71:1224–1233. [CrossRef] [PubMed] [Google Scholar]
  20. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopaedic infection in rheumatoid arthritis. Arthritis Rheum 2006;55:333–337. [CrossRef] [PubMed] [Google Scholar]
  21. Godot S, Gottenberg JE, Paternotte S, et al. Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry. Arthritis Care Res (Hoboken) 2013;65:1874–1879. [CrossRef] [Google Scholar]
  22. Hirao M, Hashimoto J, Tsuboi H, et al. Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis 2009;68:654–657. [CrossRef] [PubMed] [Google Scholar]
  23. Hirano Y, Kojima T, Kanayama Y, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. Clin Rheumatol 2010;29:495–500. [CrossRef] [PubMed] [Google Scholar]
  24. Holubar S, Eisenstein S, Bordeianou L, et al. Biologics before surgery for IBD: are they associated with post-operative infectious complications? Results from the national surgical quality improvement program inflammatory bowel disease collaborative in >1500 patients. Inflamm Bowel Dis 2021;27:S57– S58. [Google Scholar]
  25. Kawakami K, Ikari K, Kawamura K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-α blockers: perioperative interruption of tumour necrosis factor-a blockers decreases complications? Rheumatology 2010;49:341–317. [CrossRef] [PubMed] [Google Scholar]
  26. Kim JY, Zaghiyan K, Fleshner P. Risk of postoperative complications among ulcerative colitis patients treated preoperatively with vedolizumab: a matched case-control study. BMC Surg 2020;20:46. [CrossRef] [PubMed] [Google Scholar]
  27. Kubota A, Nakamura T, Miyazaki Y, et al. Perioperative complications in elective surgery in patients with rheumatoid arthritis treated with biologics. Mod Rheumatol 2012;22:844–848. [CrossRef] [PubMed] [Google Scholar]
  28. Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg 2008;12:1730–1737. [CrossRef] [PubMed] [Google Scholar]
  29. Kulaylat AN, Kulaylat AS, Schaefer EW, et al. The impact of preoperative anti-tnfα therapy on postoperative outcomes following ileocolectomy in Crohn's disease. J Gastrointest Surg 2021;25:467–474. [CrossRef] [PubMed] [Google Scholar]
  30. Latourte A, Gottenberg JE, Luxembourger C, et al. Safety of surgery in patients with rheumatoid arthritis treated by abatacept: data from the French Orencia in Rheumatoid Arthritis Registry. Rheumatology (Oxford) 2017;56:629–637. [Google Scholar]
  31. Marchal L, D'Haens G, van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004;19:749–754. [CrossRef] [PubMed] [Google Scholar]
  32. Mitsuya JB, Gonzalez R, Thomas R, et al. The effect of biologics on postoperative complications in children with inflammatory bowel disease and bowel resection. J Pediatr Gastroenterol Nutr 2019;68:334–338. [CrossRef] [PubMed] [Google Scholar]
  33. Momohara S, Kawakami K, Iwamoto T, et al. Prosthetic joint infection after total hip or knee arthroplasty in rheumatoid arthritis patients treated with non-biologic and biologic disease-modifying antirheumatic drugs. Mod Rheumatol 2011;21:469–475. [CrossRef] [PubMed] [Google Scholar]
  34. Ruyssen-Witrand A, Gossec L, Salliot C, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. Clin Exp Rheumatol 2007;25:430–436. [PubMed] [Google Scholar]
  35. Talwalkar SC, Grennan DM, Gray J. Tumour necrosis factor antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis 2005;64:650–651. [CrossRef] [PubMed] [Google Scholar]
  36. Waterman M, Xu W, Dinani A, et al. Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel disease. Gut 2013;62:387–394. [CrossRef] [PubMed] [Google Scholar]
  37. Wendling, D. Surgery in rheumatoid arthritis patients under anti-TNF-α therapy: what is the risk? Clin Rheumatol 2007;26:1396–1397. [CrossRef] [PubMed] [Google Scholar]
  38. Bakkour W, Purssell H, Chinoy H, et al. The risk of post-operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. J Eur Acad Dermatol Venereol 2016;30:86–91. [CrossRef] [PubMed] [Google Scholar]
  39. Raziyeva K, Kim Y, Zharkinbekov Z, et al. Immunology of acute and chronic wound healing. Biomolecules 2021;11:700. [CrossRef] [PubMed] [Google Scholar]
  40. Larouche J, Sheoran S, Maruyama K, et al. Immune regulation of skin wound healing: mechanisms and novel therapeutic targets. Adv Wound Care (New Rochelle) 2018;7:209–231. [CrossRef] [PubMed] [Google Scholar]
  41. Anstead GM. Steroids, retinoids, and wound healing. Adv Wound Care 1998;11:277–285. [PubMed] [Google Scholar]
  42. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:785–791. [CrossRef] [PubMed] [Google Scholar]
  43. Cusack B, Buggy DJ. Anaesthesia, analgesia, and the surgical stress response. BJA Educ 2020;20:321–328. [CrossRef] [PubMed] [Google Scholar]
  44. Watt DG, Horgan PG, McMillan DC. Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review. Surgery 2015;157:362–380. [CrossRef] [PubMed] [Google Scholar]
  45. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205–2219. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.